PERIPARTUM CARDIOMYOPATHY AS A FORM OF DILATED CARDIOMYOPATHY: A SEVERE CLINICAL CASE WITH MARKED SYSTOLIC DYSFUNCTION
Peripartum cardiomyopathy (PPCM) is a rare, potentially life-threatening form of dilated cardiomyopathy (DCM) that develops in
late pregnancy or early postpartum and causes heart failure with reduced LVEF. This paper presents a severe case in a 29-year-old
patient: LVEF on admission was 23%, NYHA class IV, and ventricular extrasystoles corresponded to Lown class IV A. The
diagnosis was confirmed by echocardiography, cardiac MRI and coronary angiography. Four-component HFrEF therapy
(sacubitril/valsartan, bisoprolol, dapagliflozin and spironolactone) increased the 6-minute walk distance from 50 to 410 m and
improved NYHA class from IV to II. The case emphasizes early diagnosis, interdisciplinary management and follow-up of PPCM
patients in the Uzbek population.
1. Roth G.A., Mensah G.A., Johnson C.O. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am
Coll Cardiol. 2020. V. 76. № 25. P. 2982–3021.
2. Arbustini E., Behr E.R., Carrier L. et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023.
V. 44. № 37. P. 3503–3626.
3. Bauersachs J., König T., van der Meer P. et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy:
a position statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2019. V. 21. № 7. P. 827–843.
4. Sliwa K., Mebazaa A., Hilfiker-Kleiner D. et al. Clinical characteristics of patients from the worldwide registry on peripartum
cardiomyopathy (PPCM): EURObservational Research Programme. Eur J Heart Fail. 2017. V. 19. № 9. P. 1131–1141.
5. Абдуллаева Г.Ж., Абдуллаев А.А., Курбанов Р.Д. Молекулярно-генетические аспекты кардиомиопатий в
Узбекистане. Кардиология Узбекистана. 2022. Т. 3. № 1. С. 12–19.
6. Bello N., Rendon I.S., Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy. J Am Coll Cardiol.
2013. V. 62. № 18. P. 1715–1723.
7. Hilfiker-Kleiner D., Kaminski K., Podewski E. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum
cardiomyopathy. Cell. 2007. V. 128. № 3. P. 589–600.
8. Ware J.S., Li J., Mazaika E. et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med.
2016. V. 374. № 3. P. 233–241.
9. McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure. Eur Heart J. 2021. V. 42. № 36. P. 3599–3726.
10. Sliwa K., Petrie M.C., van der Meer P. et al. Clinical presentation, management, and 6-month outcomes in women with
peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020. V. 41. № 39. P. 3787–3797.
11. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction.
N Engl J Med. 2019. V. 381. № 21. P. 1995–2008.
12. Packer M., Anker S.D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med.
2020. V. 383. № 15. P. 1413–1424.
Copyright (c) 2026 «ACTA NUUz»
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
.jpg)
1.png)
